Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Upfront Toripalimab Plus Axitinib Combined With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma

NCT06279403 is registered in ClinicalTrials.gov with RenJi Hospital as lead sponsor.

NCT NCT06279403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06279403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Upfront Toripalimab Plus Axitinib Combined With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
Lead sponsor
RenJi Hospital
Phase
Phase 2
Overall status
Not yet recruiting
Start date
March 1, 2024
Completion date
March 1, 2029
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

clear-cell metastatic renal cell carcinoma, cytoreductive nephrectomy, immune checkpoint inhibitors